Could a diabetes drug boost psoriasis treatment in overweight patients?
NCT ID NCT07485764
First seen Apr 06, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This study tests whether adding metformin (a diabetes drug) to secukinumab (a standard psoriasis medication) works better than secukinumab alone for controlling moderate-to-severe plaque psoriasis in overweight or obese Chinese adults. About 186 participants will receive either the combination or a placebo plus secukinumab for 60 weeks. The goal is to see if the combination leads to clearer skin and better quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.